{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T21:23:46Z","timestamp":1787261026183,"version":"build-2736575974"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T00:00:00Z","timestamp":1783296000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ctro.science","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical and Translational Radiation Oncology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ctro.2026.101234","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:12:01Z","timestamp":1783469521000},"page":"101234","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Simultaneous integrated boost vs sequential boost chemoradiotherapy in anal squamous cell carcinoma: Association with improved disease-free survival and the role of treatment delivery parameters."],"prefix":"10.1016","volume":"60","author":[{"given":"C\u00e9cile","family":"Giannetta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafik","family":"Nebbache","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Etienney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gael","family":"Goujon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Aparicio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9on","family":"Maggiori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Abramowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Qu\u00e9ro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctro.2026.101234_bb0005","series-title":"Global Cancer Observatory: Cancer Today, Incidence, Both sexes, in 2022, Anus, European Union (27)","year":"2024"},{"key":"10.1016\/j.ctro.2026.101234_bb0010","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/CEJ.0000000000000842","article-title":"Global trends in anal cancer incidence and mortality","volume":"33","author":"Mignozzi","year":"2024","journal-title":"Eur J Cancer Prev"},{"key":"10.1016\/j.ctro.2026.101234_bb0015","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0205105","article-title":"Anal cancer in high-income countries: increasing burden of disease","volume":"13","author":"Kang","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.ctro.2026.101234_bb0020","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.soc.2016.07.013","article-title":"Pathology of anal Cancer","volume":"26","author":"Hoff","year":"2017","journal-title":"Surg Oncol Clin N Am"},{"key":"10.1016\/j.ctro.2026.101234_bb0025","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/ijc.25671","article-title":"Human papillomavirus genotype distribution in anal cancer in France: the EDiTH V study","volume":"129","author":"Abramowitz","year":"2011","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ctro.2026.101234_bb0030","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR anal Cancer trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctro.2026.101234_bb0035","article-title":"Role of radiotherapy in the management of anal canal cancer: recommendations of the Soci\u00e9t\u00e9 fran\u00e7aise de radioth\u00e9rapie oncologique","volume":"29","author":"Raynaud","year":"2025","journal-title":"Cancer\/Radioth\u00e9rapie"},{"key":"10.1016\/j.ctro.2026.101234_bb0040","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.ijrobp.2021.08.008","article-title":"Long-term outcomes of NRG oncology\/RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and Mitomycin-C for the reduction of acute morbidity in Anal Canal Cancer","volume":"112","author":"Kachnic","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101234_bb0045","first-page":"100141","article-title":"Optimising chemoradiotherapy in anal cancer","author":"Franco","year":"2025","journal-title":"ESMO Gastrointest Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0050","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ajco.12768","article-title":"Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer","volume":"14","author":"Arcadipane","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0055","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/codi.16814","article-title":"Patient reported long-term side effects on bowel function and anal pain in anal cancer survivors - 3- and 6-year results from the Swedish national ANCA study","volume":"26","author":"Axelsson","year":"2024","journal-title":"Color Dis"},{"key":"10.1016\/j.ctro.2026.101234_bb0060","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/j.ejon.2015.02.007","article-title":"Late effects and quality of life after chemo-radiation for the treatment of anal cancer","volume":"19","author":"Knowles","year":"2015","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.ctro.2026.101234_bb0065","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.2340\/1651-226X.2025.43636","article-title":"Patient-reported outcomes after chemoradiotherapy for anal cancer","volume":"64","author":"Slordahl","year":"2025","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0070","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/S1470-2045(25)00213-X","article-title":"Standard versus reduced-dose chemoradiotherapy in anal cancer (PLATO-ACT4): short-term results of a phase 2 randomised controlled trial","volume":"26","author":"Gilbert","year":"2025","journal-title":"Lancet Oncol"},{"issue":"Suppl","key":"10.1016\/j.ctro.2026.101234_bb0075","doi-asserted-by":"crossref","first-page":"S183","DOI":"10.1016\/j.canrad.2016.07.061","article-title":"Radiotherapy for anal canal cancers","volume":"20","author":"Peiffert","year":"2016","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.ctro.2026.101234_bb0080","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.canrad.2021.11.015","article-title":"Radiotherapy of anal canal cancer","volume":"26","author":"Peiffert","year":"2022","journal-title":"Cancer Radiother"},{"key":"10.1016\/j.ctro.2026.101234_bb0085","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1038\/nrc1650","article-title":"Repopulation of cancer cells during therapy: an important cause of treatment failure","volume":"5","author":"Kim","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctro.2026.101234_bb0090","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.ejca.2019.08.022","article-title":"Pooled analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in anal Cancer (PARADAC)","volume":"121","author":"Rivin Del Campo","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctro.2026.101234_bb0095","doi-asserted-by":"crossref","first-page":"5061","DOI":"10.1200\/JCO.2010.29.1351","article-title":"Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of radiation therapy oncology group trials 87-04 and 98-11","volume":"28","author":"Ben-Josef","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0100","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.annonc.2020.06.012","article-title":"Impact of compliance to chemoradiation on long-term outcomes in squamous cell carcinoma of the anus: results of a post hoc analysis from the randomised phase III ACT II trial","volume":"31","author":"Glynne-Jones","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.21037\/jgo.2020.02.09","article-title":"Impact of radiotherapy duration on overall survival in squamous cell carcinoma of the anus","volume":"11","author":"Mehta","year":"2020","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0110","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00384-009-0775-2","article-title":"Anal cancer treated with radio-chemotherapy: correlation between length of treatment interruption and outcome","volume":"24","author":"Janssen","year":"2009","journal-title":"Int J Colorectal Dis"},{"key":"10.1016\/j.ctro.2026.101234_bb0115","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.ijrobp.2007.12.027","article-title":"Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08","volume":"72","author":"Konski","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101234_bb0120","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1080\/02841860600726729","article-title":"Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome","volume":"45","author":"Meyer","year":"2006","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0125","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1001\/jamaoncol.2020.0809","article-title":"Factors associated with Chemoradiation therapy interruption and noncompletion among patients with squamous cell anal carcinoma","volume":"6","author":"Raphael","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0130","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s10350-007-9125-z","article-title":"Squamous-cell carcinoma of the anal canal: predictors of treatment outcome","volume":"51","author":"Roohipour","year":"2008","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.ctro.2026.101234_bb0135","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/S0140-6736(24)02319-5","article-title":"Radiotherapy toxicities: mechanisms, management, and future directions","volume":"405","author":"Verginadis","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.ctro.2026.101234_bb0140","first-page":"39","article-title":"Intensity-modulated radiation therapy vs. 3D conformal radiation therapy for squamous cell carcinoma of the anal canal","volume":"6","author":"Chuong","year":"2013","journal-title":"Gastrointest Cancer Res"},{"key":"10.1016\/j.ctro.2026.101234_bb0145","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: a phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101234_bb0150","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.ijrobp.2012.12.008","article-title":"Simultaneous integrated boost-intensity modulated radiation therapy with concomitant capecitabine and mitomycin C for locally advanced anal carcinoma: a phase 1 study","volume":"85","author":"Deenen","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"15_suppl","key":"10.1016\/j.ctro.2026.101234_bb0155","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e15501","article-title":"Interim analysis of a phase II study of simultaneously integrated boost intensity modulated radiation therapy (SIB-IMRT) in combination with 5-FU and mitomycin-C among patients with locally advanced anal canal cancer","volume":"39","author":"Florescu","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0160","first-page":"1943","article-title":"Early-stage node-negative (T1-T2N0) anal Cancer treated with simultaneous integrated boost radiotherapy and concurrent chemotherapy","volume":"36","author":"Franco","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctro.2026.101234_bb0165","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ijrobp.2010.09.030","article-title":"Dose-painted intensity-modulated radiation therapy for anal cancer: a multi-institutional report of acute toxicity and response to therapy","volume":"82","author":"Kachnic","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101234_bb0170","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00432-018-2608-6","article-title":"Modern intensity-modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients","volume":"144","author":"De Bari","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0175","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0180","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1186\/s13014-018-1124-9","article-title":"Comparing simultaneous integrated boost vs sequential boost in anal cancer patients: results of a retrospective observational study","volume":"13","author":"Franco","year":"2018","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0185","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1634\/theoncologist.2019-0759","article-title":"Chemoradiation-related lymphopenia and its association with survival in patients with squamous cell carcinoma of the Anal Canal","volume":"25","author":"Lee","year":"2020","journal-title":"Oncologist"},{"key":"10.1016\/j.ctro.2026.101234_bb0190","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s10147-021-02094-5","article-title":"Prognostic impact of neutrophilia and lymphopenia on survival in anal cancer treated with definitive concurrent chemoradiotherapy: a retrospective multicenter study","volume":"27","author":"Kim","year":"2022","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0195","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.21037\/jgo-21-323","article-title":"Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma","volume":"12","author":"De","year":"2021","journal-title":"J Gastrointest Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0200","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","article-title":"The influence of severe radiation-induced lymphopenia on overall survival in solid tumors: A systematic review and Meta-analysis","volume":"111","author":"Damen","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ctro.2026.101234_bb0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2025.109702","article-title":"Impact of circulating lymphocyte kinetics following radiotherapy on patient survival: A model-based meta-analysis","volume":"186","author":"Pham","year":"2025","journal-title":"Comput Biol Med"},{"key":"10.1016\/j.ctro.2026.101234_bb0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2023.110041","article-title":"Modeling frameworks for radiation induced lymphopenia: A critical review","volume":"190","author":"Cella","year":"2024","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ctro.2026.101234_bb0215","doi-asserted-by":"crossref","first-page":"5774","DOI":"10.3390\/curroncol31100429","article-title":"Lymphopenia induced by different neoadjuvant chemo-radiotherapy schedules in patients with rectal Cancer: bone marrow as an organ at risk","volume":"31","author":"Nanos","year":"2024","journal-title":"Curr Oncol"}],"container-title":["Clinical and Translational Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001291?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405630826001291?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T20:26:04Z","timestamp":1787257564000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405630826001291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"alternative-id":["S2405630826001291"],"URL":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101234","relation":{},"ISSN":["2405-6308"],"issn-type":[{"value":"2405-6308","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Simultaneous integrated boost vs sequential boost chemoradiotherapy in anal squamous cell carcinoma: Association with improved disease-free survival and the role of treatment delivery parameters.","name":"articletitle","label":"Article Title"},{"value":"Clinical and Translational Radiation Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctro.2026.101234","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of European Society for Radiotherapy and Oncology.","name":"copyright","label":"Copyright"}],"article-number":"101234"}}